Evidence map›Paper›PMID 36465942›Full record

ArticleFrontiers in medicine2022

Dynamic inflammatory response among routine laboratory biomarkers and their predictive ability for mortality in patients with severe COVID-19.

Arturo Cortes-Telles, Ana Ligia Gutiérrez-Solis, Víctor Aarón Álvarez-Sánchez, Alejandro Gabriel González-Garay, Roberto Lugo, Azalia Avila-Nava

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Arturo Cortes-TellesClinica de Enfermedades Respiratorias, Hospital Regional de Alta Especialidad de la Península de Yucatán, Mérida, Mexico.
Ana Ligia Gutiérrez-SolisUnidad de Investigación, Hospital Regional de Alta Especialidad de la Península de Yucatán, Mérida, Mexico.
Víctor Aarón Álvarez-SánchezDepartamento de Medicina Interna, Hospital Regional de Alta Especialidad de la Península de Yucatan, Mérida, Mexico.
Alejandro Gabriel González-GarayDepartamento de Metodología de la Investigación, Instituto Nacional de Pediatría, Ciudad de México, Mexico.
Roberto LugoUnidad de Investigación, Hospital Regional de Alta Especialidad de la Península de Yucatán, Mérida, Mexico.
Azalia Avila-NavaUnidad de Investigación, Hospital Regional de Alta Especialidad de la Península de Yucatán, Mérida, Mexico.
Hospital Regional de Alta Especialidad del Bajío · MXInstituto Nacional de Pediatria · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The severity of coronavirus disease 2019 (COVID-19) is related to several factors, including age, sex, and comorbidities (obesity, type 2 diabetes, and hypertension). However, systemic inflammation plays a fundamental role in COVID-19 pathophysiology. Several studies have described this association employing specific biomarkers that are not routinely used in clinical practice. On the other hand, very few reports in the literature focused on the analysis of the routine laboratory biomarkers to predict the outcome of severe COVID-19 patients. Objective: We aimed to analyze the dynamic inflammatory response using routine laboratory biomarkers to predict in-hospital mortality in Mexican patients with severe COVID-19. Methods: This is a cohort study including patients with severe COVID-19. Demographic characteristics were retrieved from medical charts and biochemical parameters were measured at hospital admission and subsequently on days 3, 5, 7, 10, 14, and 21 during the hospital stay; measurements were stopped when patients were discharged from the hospital (alive or death). Results: A total of 250 patients were included in the study, 40.8% of patients died. The analyzed routine laboratory parameters, such as serum levels of neutrophil-to-lymphocyte ratio, C-reactive protein, and D-dimer remained elevated in hospitalized patients who did not survive, whereas eosinophil and platelets were maintained at lower levels. In the multivariate analysis, leukocytes, and neutrophils were the best biomarkers for predicting mortality risk and were independent of age, gender, or comorbidities. Conclusion: Our results support the use of routine laboratory biomarkers as predictors of mortality in Mexican hospitalized patients with severe COVID-19.

Indexed as

CRPD-dimerleukocytesMexican populationneutrophilsSARS-CoV-2

Identifiers

PMID36465942
PMCPMC9714476
OpenAlexW4309174491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.